Table 1.
Animal Use in the Experiments
| Experiment | Cells | Animal strain and total numbers | Groups |
|---|---|---|---|
| Immunomodulation properties of BMMSCs T cell apoptosis; Th1, Th2, Th17, and Treg cell induction |
BMMSCs for coculture T lymphocytes |
C57BL/6J, female, 8-week-old, 10 mice C57BL/6J, female, 8-week-old, 10 mice |
Three wells for each group. The experiments were repeated five times Group 1: naive T cells (negative control) Group 2: active T cells (positive control) Group 3: Coculture BMMSCs with active T cell |
| Allogenic mouse BMMSC implantation | BMMSCs for implants BMMSCs for systemic infusion |
C3H/HeJ mice, female, 8-week-old, five mice (totally about 8×107 BMMSCs) C57BL/6J mice, female, 8-week-old one mouse Receipt mice: immunocompromised mice, female, 8-week-old, two mice C57BL/6J mice, female, 8-week-old, nine mice |
BMMSCs (C3H/HeJ)/HA/TCP were implanted to C57BL/6J mice or immunocompromised mice, harvested at 8 weeks postimplantation Group 1: BMMSCs/HA/TCP in immunocompromised mice (five implants in two mice) Group 2: BMMSCs/HA/TCP in C57BL/6J mice (five implants in three mice) Group 3: BMMSCs/HA/TCP in C57BL/6J mice with BMMSCs iv. (five implants in three mice) Group 4: BMMSCs/HA/TCP in C57BL/6J mice with BMMSCs iv. and anti-CD25 antibody (five implants in three mice) |
| Cytokine levels | BMMSCs for implants BMMSCs for systemic infusion |
C3H/HeJ mice, female, 8-week-old, 15 mice (totally about 2.4×108 BMMSCs) C57BL/6J mice, female, 8-week-old, five mice Receipt mice: C57BL/6J mice, female, 8-week-old, 60 mice |
BMMSCs (C3H/HeJ)/HA/TCP were implanted to C57BL/6J mice; harvested at 2, 4, 7, and 14 days postimplantation; five implants at each time point, one implant per mouse Group 1: HA/TCP in C57BL/6J mice (20 implants in 20 mice) Group 2: BMMSCs/HA/TCP in C57BL/6J mice (20 implants in 20 mice) Group 3: BMMSCs/HA/TCP in C57BL/6J mice with BMMSCs iv. (20 implants in 20 mice) |
| Surviving cells in BMMSC implants | BMMSCs for implants (labeled in red color with PKH26) BMMSCs for systemic infusion |
C3H/HeJ mice, female, 8-week-old, 10 mice (totally about 1.6×108 BMMSCs) C57BL/6J mice, female, 8-week-old, three mice Receipt mice: C57BL/6J mice, female, 8-week-old, 40 mice |
BMMSCs (C3H/HeJ mice)/gelfoam were implanted to C57BL/6J mice; harvested at 3, 7, 14, and 28 days postimplantation; five implants at each time point, one implant per mouse Group 1: BMMSCs/gelfoam in C57BL/6J mice (20 implants in 20 mice) Group 2: BMMSCs/gelfoam in C57BL/6J mice with BMMSCs iv. (20 implants in 20 mice) |
| Anti-ALP and TRAP double staining | BMMSCs for implants BMMSCs for systemic infusion |
C3H/HeJ mice, female, 8-week-old, three mice (totally about 4×107 BMMSCs) C57BL/6J mice, female, 8-week-old, one mice Receipt mice: C57BL/6J mice, female, 8-week-old, 10 mice |
BMMSCs (C3H/HeJ mice)/HA/TCP were implanted to C57BL/6J mice, harvested at 3 weeks postimplantation, one implant per mouse Group 1: BMMSCs/HA/TCP in C57BL/6J mice (five implants in five mice) Group 2: BMMSCs/HA/TCP in C57BL/6J mice with BMMSCs iv. (five implants in five mice) |
| Homing of systemic infused BMMSCs to implants | BMMSCs for implants BMMSCs for systemic infusion |
C3H/HeJ mice, female, 8-week-old, five mice (totally about 8×107 BMMSCs) C57BL/6-Tg (ACTB-EGFP)1Osb/J, female, 8-week-old, five mice Receipt mice: C57BL/6J mice, female, 8-week-old, 20 mice |
Group 1: BMMSCs (C3H/HeJ mice)/gelfoam were implanted to C57BL/6J mice after BMMSCs[C57BL/6-Tg (ACTB-EGFP)1Osb/J] iv., and harvested at the first day postimplantation (five implants in five mice) Group 2: same as group 1, and harvested at the third day postimplantation (five implants in five mice) Group 3: same as group 1, and harvested at the fifth day postimplantation (five implants in five mice) Group 4: same as group 1, and harvested at the seventh day postimplantation (five implants in five mice) |
| Calvarial defect reparation | BMMSCs for reparation BMMSCs for systemic infusion |
C57BL/6J mice, female, 8-week-old, four mice (totally about 6×107 BMMSCs) C57BL/6J mice, female, 8-week-old, two mice Receipt mice: C57BL/6J mice, female, 8-week-old, 15 mice |
Group 1: HA/TCP were implanted to calvarial defects of C57BL/6J mice (five mice) Group 2: BMMSCs (C57BL/6J mice)/HA/TCP were implanted to calvarial defects of C57BL/6J mice (five mice) Group 3: BMMSCs (C57BL/6J mice)/HA/TCP were implanted to calvarial defects of C57BL/6J mice after BMMSCs iv. (five mice) |
BMMSCs iv., mean systemic infusion of BMMSCs via tail vein.
BMMSC, bone marrow mesenchymal stem cell; HA/TCP, hydroxyapatite/tricalcium phosphate.